Polymorphisms of the Dopamine Receptor Gene DRD2 and Colorectal Cancer Risk

Sporadic colorectal cancer is considered a multifactorial disease in which multiple exposures interact with the individual genetic background resulting in risk modulation. Recent experimental data suggest a role of dopamine and dopamine receptors in the control of proliferation of the cells of colon and gastrointestinal tract. To investigate whether polymorphisms within dopamine receptors genes could have a role in modulating the risk of sporadic colorectal cancer, we did a case-control association study and genotyped 370 cases and 327 controls for seven single-nucleotide polymorphisms (SNP) of DRD2 (−141Cdel, 957T>C, TaqIB, TaqIA, 1412A>G, S311C, and 3208G>T) by a microarray-based technique. Three SNPs within DRD2 were associated with colorectal cancer, with a maximum odds ratio of 2.28 (95% confidence interval, 1.38-3.76) for carriers of the functional SNP −141Cdel. The haplotype which includes −141Cdel, together with the variants 957C and 1412G, shows an odds ratio of 2.86 (95% confidence interval, 1.58-5.18), as compared with the most frequent haplotype. The SNPs within DRD2 associated with colorectal cancer are known to be related to reduced levels of D2 dopamine receptor. Thus, our data point to a possible role of dopamine receptor DRD2 in modulating the risk of colorectal cancer. Future studies on dopamine receptor–mediated signal transduction may provide new insight into the mechanisms of colorectal cancer and suggest new therapeutic strategies.

[1]  S. David,et al.  Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[2]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[3]  Federica Gemignani,et al.  Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair. , 2003, BioTechniques.

[4]  J. Baik,et al.  Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells , 2003, Molecular and Cellular Endocrinology.

[5]  D. Melton,et al.  Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer , 2003, British Journal of Cancer.

[6]  Stefano Landi,et al.  Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. , 2003, Cancer research.

[7]  Y. Akao,et al.  Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer , 2003, Journal of Molecular Medicine.

[8]  N. Saitou,et al.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. , 2003, Human molecular genetics.

[9]  E. D. de Vries,et al.  Low-penetrance genes and their involvement in colorectal cancer susceptibility. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  Giovanni Romeo,et al.  Reliable Detection of β-Thalassemia and G6PD Mutations by a DNA Microarray , 2002 .

[11]  F. Canzian,et al.  A catalogue of polymorphisms related to xenobiotic metabolism and cancer susceptibility. , 2002, Pharmacogenetics (London).

[12]  R. Houlston,et al.  Polymorphisms and colorectal tumor risk. , 2001, Gastroenterology.

[13]  T. Kondo,et al.  Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. , 2001, American journal of medical genetics.

[14]  E P Noble,et al.  The DRD2 gene in psychiatric and neurological disorders and its phenotypes. , 2000, Pharmacogenomics.

[15]  S. Basu,et al.  Decreased Dopamine Receptor Expression and Its Second-Messenger cAMP in Malignant Human Colon Tissue , 1999, Digestive Diseases and Sciences.

[16]  D. Collier,et al.  Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia , 1998, Schizophrenia Research.

[17]  T Nagatsu,et al.  DRD2 allele frequencies and linkage disequilibria, including the -141CIns/Del promoter polymorphism, in European-American, African-American, and Japanese subjects. , 1998, Genomics.

[18]  J O Rinne,et al.  The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers , 1998, Molecular Psychiatry.

[19]  E. Noble.  The DRD2 gene, smoking, and lung cancer. , 1998, Journal of the National Cancer Institute.

[20]  E K Perry,et al.  D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. , 1997, Pharmacogenetics.

[21]  É. Mezey,et al.  Substantial production of dopamine in the human gastrointestinal tract. , 1997, The Journal of clinical endocrinology and metabolism.

[22]  G. Teuchert-Noodt,et al.  Dopamine and the regulation of cell proliferation in gerbil (Meriones unguiculatus) pyloric mucosa. , 1997, Life sciences.

[23]  T. Arinami,et al.  A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. , 1997, Human molecular genetics.

[24]  T. Biden,et al.  Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. , 1992, Molecular Endocrinology.

[25]  S. Szabó,et al.  Dopamine in gastrointestinal disease , 1990, Digestive Diseases and Sciences.

[26]  M. Tatematsu,et al.  Epithelial cell proliferation in rat forestomach and glandular stomach mucosa induced by catechol and analogous dihydroxybenzenes. , 1990, Carcinogenesis.

[27]  J. Wallace,et al.  A role for dopamine as an endogenous protective factor in the rat stomach. , 1989, Gastroenterology.

[28]  P. Tagliaferri,et al.  Synergistic inhibition of growth of breast and colon human cancer cell lines by site-selective cyclic AMP analogues. , 1988, Cancer research.

[29]  Nathaniel Rothman,et al.  Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. , 2004, Journal of the National Cancer Institute.

[30]  E. Noble,et al.  Association of Seven Polymorphisms of the D2 Dopamine Receptor Gene with Brain Receptor-Binding Characteristics , 2004, Neurochemical Research.

[31]  Cancer Epidemiol Biomarkers Prev , 2004 .

[32]  E. Noble,et al.  D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[33]  A. Metspalu,et al.  Arrayed primer extension: solid-phase four-color DNA resequencing and mutation detection technology. , 2000, Genetic testing.

[34]  A. Metspalu,et al.  DNA resequencing, mutation detection and gene expression analysis by oligonucleotide microchips , 1999 .

[35]  Relative Validity and Reproducibility of a Diet History Questionnaire in Spain. I. Foods , 1997 .

[36]  A. Rolfs,et al.  Dopamine D2 receptor gene (DRD2) haplotypes in Caucasians. , 1996, Gene.

[37]  A. Thiel,et al.  Direct fluorescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports. , 1994, Nucleic acids research.

[38]  HighWire Press,et al.  Cancer epidemiology biomarkers & prevention , 1991 .